Showing 4621-4630 of 6036 results for "".
- Report: Diagnosed Cases of AMD in the Seven Major Markets Expected to Grow Over Next 10 Yearshttps://modernod.com/news/report-diagnosed-cases-of-amd-in-the-seven-major-markets-expected-to-grow-over-next-10-years/2480979/Diagnosed prevalent cases of age-related macular degeneration (AMD) in the seven major markets combined is expected to increase from 33.66 million cases in 2021 to 40.32 million in 2031, at an annual growth rate (AGR) of 1.98%, according to GlobalData. Of the seven major mark
- Verana Health Presents Geographic Atrophy and Diabetic Macular Edema Research at ASRS 2022https://modernod.com/news/verana-health-presents-geographic-atrophy-and-diabetic-macular-edema-research-at-asrs-2022/2480976/Verana Health delivered two podium presentations at the American Society of Retina Specialists annual meeting in New York City on July 15. The research findings were generated through analysis of Ophthalmology Qdata, real-world data resulting from the curation
- Apellis Announces FDA Acceptance and Priority Review of the NDA for Pegcetacoplan for the Treatment of Geographic Atrophyhttps://modernod.com/news/apellis-announces-fda-acceptance-and-priority-review-of-the-nda-for-pegcetacoplan-for-the-treatment-of-geographic-atrophy/2480973/Apellis Pharmaceuticals announced that the FDA has accepted and granted Priority Review designation for the intravitreal pegcetacoplan new drug application (NDA). Pegcetacoplan is an investigational, targeted C3 therapy for the treatment of geographic atrophy (GA) secondary to age-relat
- Bausch + Lomb and Novaliq Submit New Drug Application for Investigational NOV03 for Dry Eye Disease Associated with MGDhttps://modernod.com/news/bausch-lomb-and-novaliq-submission-new-drug-application-for-investigational-nov03-for-dry-eye-disease-associated-with-mgd/2480972/Bausch + Lomb and Novaliq announced the submission of a new drug application (NDA) at the end of June to FDA seeking approval for NOV03 (perfluorohexyloctane), an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease (DED) associated
- New App Allows Surgeons to Search for FDA Approved IOLshttps://modernod.com/news/new-app-allows-surgeons-to-search-for-fda-approved-iols/2480969/Matt Hirabayashi, MD, of eyeflymd.com, and Gurpal Virdi, MD, of Eyelabs.ai, have developed an app called “eyeSpace,” which is designed to allow surgeons and trainees to
- American Academy of Optometry Launches Nationwide Search for New CEOhttps://modernod.com/news/american-academy-of-optometry-launches-nationwide-search-for-new-ceo/2480968/The American Academy of Optometry (AAO) has formed a search committee to identify candidates for the position of Chief Executive Officer. Current Chief Financial Officer (CFO)/Deputy CEO Richard Jones will serve as Interim Chief Executive Officer throughout the search. Mr. Jones has more than 20
- After Building New Plant and Signing on with AbbVie, Regenxbio Enters Commercial Phasehttps://modernod.com/news/after-building-new-plant-and-signing-on-with-abbvie-regenxbio-enters-commercial-phase/2480967/An article in FiercePharma details the expansion plans of Regenxbio—with its new building as tangible evidence of its arrival as a burgeoning commercial busines
- Genentech: New 2-Year Data Confirm Vabysmo Improves Vision With Fewer Treatments for Wet AMDhttps://modernod.com/news/genentech-new-two-year-data-confirm-vabysmo-improves-vision-with-fewer-treatments-for-people-with-wet-amd/2480965/Genentech announced new 2-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo (faricimab-svoa) in wet age-related macular degeneration (AMD). The 2-year data were presented at the 2022 American Society of Retina Specialis
- Euclid Vision Announces Official Launch of Cloud-Based Portalhttps://modernod.com/news/euclid-vision-announces-official-launch-of-cloud-based-portal/2480964/Euclid Vision has announced the official rollout of MyEuclid, an interactive, web-based customer portal designed to drive practice efficiency and optimize Euclid Ortho-K fits. The MyEuclid portal was released on a limited basis earlier this year, and the platform is now availa
- Xequel Bio Announces Positive Results from Phase 1b Study of iNexin, a Novel aCT1 Ophthalmic Solutionhttps://modernod.com/news/xequel-bio-announces-positive-results-from-phase-1b-study-of-inexin-a-novel-act1-ophthalmic-solution/2480963/Xequel Bio announced positive results from its phase 1b clinical trial with iNexin (aCT1 ophthalmic solution) for the treatment of corneal injury in patients with dry eye disease. The study demonstrated that iNexin was safe and well-tolerated at the doses tested, and ear